TEL AVIV, Israel, March 6, 2023 /PRNewswire/ -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that management will be presenting a corporate overview and participating in 1-on-1 meetings at the Oppenheimer 33rd Annual Healthcare Conference on Wednesday March 15, 2023. The conference format this year is virtual.
Read more at prnewswire.comProvided Content: Content provided by PR Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.